Innovating Novel Immunotoxin Antibody Assets

Company Overview

May 2021

Innovating Novel Immunotoxin Antibody Assetshttp://www.fatiabgen.com

http://www.fatiabgen.com/

PROPRIETARY AND CONFIDENTIAL © 2021 Fatiabgen

Not For Disclosure Or Use Without Permission.

Except for statements of historical fact, the statements in this presentation are forward-looking statements, including, but not limited to, statements

regarding the future development of our proprietary technology; These statements constitute "forward-looking statements" within the meaning of Section

27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates,“, "believes,"

"estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. These forward-

looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information

currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as

reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies

will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by

a variety of risks and factors that are beyond our control. These statements involve risks and uncertainties that can cause actual results to differ materially

from those in such forward-looking statements. Important factors that may cause actual results to differ materially from the results discussed in the forward-

looking statements include risks and uncertainties, including (1) our failure to secure and maintain relationships with collaborators; (2) risks relating to clinical

trials and other uncertainties of product candidate development; (3) risks relating to the commercialization, if any, of our proposed product candidates

(such as marketing, regulatory, product liability, supply, competition, and other risks); (4) dependence on the efforts of third parties including our strategic

partners; (5) dependence on intellectual property; and (6) risks from global pandemics including COVID-19. Existing and prospective investors are cautioned

not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These forward-looking statements reflect

management’s current views and we do not undertake to update any of these forward-looking statements to reflect a change in events or circumstances that

occur after the date of this presentation except as required by law.

2

Disclaimer



Company Overview

Founded March 2020 Located Songpa, Seoul, Korea

Capital KRW 308 Mn (617,000 shares) Employees 11 (R&D 6 / Sales & Admin 5)

Ownership Key Management : 70% / Angel: 30% Stage Seeding stage

Market Cap KRW 9.18 Bn ($8.2 M) Status Venture Company (06/20~06/22)

3

In/Out Licensing

Biotech company using advanced cancer therapeutics

Core Technology Business Model R&D Strategy

Paper/Patent Assetization

Research/development collaborationNext Generation Recombinant Immunotoxin

Open Innovation

Unique Mode-of-Action

Develop drug delivery system against complex target cancer

Platform/Pipeline development



• Dr. Hanseok Choe currently working in Asan Hospital specialized in immunotoxin research and patents were foundation elements for Fatiabgen’s R&D

• Fatiabgen’s private market value of $8.2M after the latest funding round in August 2020

• Dr. Jungche Lim, an antibody expert, joined Fatiabgen from Y-Biologics to lead immunotoxin research.

• Joint R&D collaboration with Y-Biologics, Chunnam University, and Wonkwang university

4

Company History

2015

2018

Q1, 2021

2020. 03

2020. 08

• Dr. HanseokChoe initiated immunotoxin research from his own lab

• Dr. HanseokChoe Published several immunotoxin related papers

• Acquire immunotoxin related patents for further development

• March 2020: Establish‘Fatiabgen’ (Appoint Dr. Han seok Choe as SBA)

• Aug 2020: Capital increase by issuing new stock (Post value: $8.2M)

• Feb 2021: Appointed Jungche Lim as Vice President & CSO in Fatiabgen

• Dec 2020: Appointed JayJay Lee as CEO & Investor

• May 2020: License-in 6 Patents from Dr. Hanseok Choe

• March 2021: Appointed Gunseop Lee as CTO in Fatiabgen

Q2, 2021

• April 2021: Joint R&D with Y-Biologics: Discovery of Antibody target Pancreatic cancer

• April 2021: Joint R&D with ChunnamUniversity: Discovery of Toxin target solid cancer tumors

PROPRIETARY AND CONFIDENTIAL © 2021 FatiAbGen


Fatiabgen’s people

5


Not For Disclosure Or Use Without Permission.6

Chief Executive Office Vice President / Chief Science Officer

JayJay LeeChief Executive OfficerGlobal, Startup company expert

Over 17 years of serving Leadership position from global companies as well as startup companies with business success & growth

EducationB.A. at Yonsei University Kyunggi High School

ExperienceCountry Manager Korea / Japan : Targus LLCGlobal Senior Director : AnymodeCorporationCountry Manager Korea : Belkin International

Awards2015: Highest Performance Leader in Asia region : Targus LLC2007: Highest Net Sales Achievement in Asia region: Belkin International

Jungchae, LimVice President / Chief Science OfficerTherapeutic antibody expert

Major contribution: Responsible for research collaboration with LegoChem biosciences and Pyxis Oncology worth $294M (Upfront $9.5M)

EducationPh.D. Biochemistry, Chonnam national universityM.S. Biochemistry, Chonnam national universityB.S. Genetic engineering, Sungkyunkwan University

ExperienceChief Science Officer : Y-BiologicsVisiting Fellow: NIH, MD, USA

Awards2014: Research achievement: NIH



Co-founder / Scientific Board Advisor Chief Technology Officer

Gunsup, LeeChief Technology Officer & PhD

Scientist participate over 30 scientific journal, owned 4 patents related to animal / DNA viruses

EducationPh.D., Department of Genetic Engineering, Sungkyunkwan University, Graduate School, Korea.Thesis : Preventive and therapeutic effects by 3D8 scFv against Herpesviridae infections on HeLa cells and C57BL/6 mice

Experience2019 – 2020 : Chief researcher (Novelgen)2016–2018: Postdoctoral fellow (NationalInstitute of Animal Science)2015 – 2016: Chief of research department(Tooth Stem Cell Bank Inc.)2011 – 2013 : Postdoctoral fellow (KoreaInstitute of Ocean Science and Technology)

Hanseok ChoeProfessor & PhD

Pioneer Immunotoxin research & development

Education• Ph.D., Physiology and Biophysics. Cornell University Weill Graduate School of Medical Sciences, New York, NY 10021, USA.• MS, Neuroscience. Seoul National University, Graduate School of Natural Science, Seoul, Korea.• BS, Molecular Biology. Seoul National University, College of Natural Science, Seoul, Korea.

Experience• Professor, University of Ulsan College of Medicine, Seoul, Korea• Postdoctoral Fellow, Department of Pharmacology Institute of Cardiovascular Research, Chonbuk National University, Chonju, Korea• Postdoctoral Fellow, The Salk Institute for Biological Studies, Structural Biology Laboratory, CA, USA• Postdoctoral Fellow, Dept. Physiology and Biophysics, Cornell University Weill Medical College, NY, USA• Research Assistant, Pohang University of Science and Technology, Pohang, Korea



Scientific Advisor Board members

Chong-Hwan ChangCEO of MetiMedi Pharmaceuticals

Education• Ph.D., Structural Biology. University of Pittsburgh, Department of Structural Biology, USA• MS, Physical Chemistry. Seoul National University, College of Natural Science, Seoul, Korea• BS, Physical Chemistry. Seoul National University, College of Natural Science, Seoul, Korea

Dr. SANG HYUN MOH CEO/CTO of BIO-FD&C Co., Ltd

Education• Ph.D., Sungkyunkwan University SAINT, Suwon.• MS, Gwangju Institute of Science and Technology (GIST), Gwangju.• BS, Sungkyunkwan University Genetic Engineering, Suwon.

PROFESSIONAL AFFILIATE• 2014-2016 President, Antibody Society of Korea• 2013-2016 Board Member, BioConvergence• 2012-2016 Board Member, Scripps Korea Antibody Institute• 2011-2013 Board Member, Korea Drug Development Fund (KDDF)• 2010-2012 Adjunct Professor, College of Pharmacy, Seoul National University• 2006-2009 Member of the BioCluster Build up, Korean Government

Experience• Vice President, CTO Green Cross Corp.• Director, Bristol-Myers Squibb, Molecular Biosciences• Director, head of protein crystallography group. DuPont Pharmaceutical Company• Biophysicist, Argonne National Laboratory

Experience• CEO/CTO of BIO-FD&C Co., Ltd / Project Leader in Nanobioscience and Stem Cells.• Adjunct Professor, School of Global Entrepreneurship and Information Communication Technology, Handong Global University.• Outpatient Professor, College of Medicine, Chung Ang University• Director, The Asian Society of Natural Products



R&D Collaboration Partnership - Academic

Chungoo Park, Ph.D.Professor, Chonnam National University

Education• Ph.D., Biology; Molecular Evolutionary Biology option, The Pennsylvania State University, University Park, PA, USA • M.S., Computer Science, Gwangju Institute of Science and Technology, Gwangju, Korea • B.S., Computer Science & Engineering, Inha University, Incheon, South Korea

Jae Ho Seo, Ph.D.Professor, Wonkwang University

Education• Ph.D., School of Biological Sciences and Technology, Chonnam National University, Gwangju, Korea.• M.S., Dept. of Biology, Chonnam National University, Gwangju, Korea Thesis: Radiation induced C-terminal truncation of mouse pancreatic Prx II • B.S., Dept. of Biological Sciences, Chonnam National University, Gwangju, Korea

PROFESSIONAL AFFILIATE• Postdoctoral IRTA Fellow, Program in Genomics of Differentiation, National Institute of Child Health and Human Development, National Institutes of Health• Postdoctoral Research Fellow, Department of Ecology and Evolutionary Biology, University of Michigan

Publications (Journal)• Comparability of reference-based and reference-free transcriptome analysis approaches at the gene expression level. BMC Bioinformatics (2020) (in press)• Paralogs and Isoforms Classifier based on Machine-learning approaches. BMC Bioinformatics. (2020) (in press)• Lipocalin2 Induced by Bacterial Flagellin Protects Mice against Cyclophosphamide Mediated Neutropenic Sepsis. Microorganisms. (2020) 8(5): 646• Identification of Differentially Expressed Genes Associated with Extracellular Matrix Degradation and Inflammatory regulation in Calcific Tendinopathy using RNA Sequencing. Calcified Tissue International. (2020)

PROFESSIONAL AFFILIATE• Research Professor, Hypoxia-related Disease Research Center, College of Medicine, InhaUniversity, Incheon, Korea• Associate Staff Scientist, Wistar Institute, Philadelphia, PA, USA• Postdoc Fellow, Wistar Institute, Philadelphia, PA, USA• Postdoc Fellow, Winship Cancer Institute in Emory University, Atlanta, GA, USA • Visiting Research, Lab of Biochemistry/NHLBI/NIH, Bethesda, MD, USA

Publications (Journal)• The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells. Sci signal. 2020,13(642): eaaz8240• Latifolin inhibits oxidative stress-induced senescence via upregulation of SIRT1 in human dermal fibroblasts. Biol Pharm Bull. 2020,43(7): 1104-1110• Mitochondrial fission factor is a novel Myc-dependent regulator of mitochondrial permeability in cancer. EBioMedicine. (* These authors are contributed equally) 2019, 48: 353-363.• Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. J Biol Chem. 2019, 294(27): 10407-10414





Market Landscape – ADC / Immunotoxin

10



• Global ADC market is expected to reach $13.6 bn in 2025, compared with $2.6 bn in 2019 CAGR of 31.6%

• Up to date, total of 10 ADCs have been approved by the FDA. 7 ADCs approved after 2017.

• More than 80 ADCs undergoing clinical trials as of June 2020

11

Antibody-Drug Conjugates(ADC) Market Landscape

Drug Maker Condition Trade nameApproval

Year

Annual Revenue

Forecast

Gemtuzumab ozogamicin Pfizer/Wyeth relapsed acute myelogenous leukemia (AML) Mylotarg 2017;2000 N/A

Brentuximab vedotinSeattle Genetics,

Millennium/Takedarelapsed HL and relapsed sALCL Adcetris 2011 Over $1B

Trastuzumab emtansineGenentech,

RocheHER2-positive metastatic breast cancer (mBC) following treatment with trastuzumab and a maytansinoid. First solid tumor treatment.

Kadcyla 2013 $1.4B (2019)

Inotuzumab ozogamicin Pfizer/Wyeth relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia Besponsa 2017 Potential $2B

Polatuzumab vedotin-piiq Genentech, Roche relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Polivy 2019 $56M

Enfortumab vedotinAstellas

/Seattle Geneticsadult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy

Padcev 2019 Est $250M (2020)

Trastuzumab deruxtecanAstraZeneca

/Daiichi Sankyoadult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens

Enhertu 2019 $336M (2020)

Sacituzumab govitecan Immunomedicsadult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease

Trodelvy 2020 Est $100M

Belantamab mafodotin-blmf GlaxoSmithKline (GSK) adult patients with relapsed or refractory multiple myeloma Blenrep 2020 Potential $1.6B

$2.6 bn

$13.6 bn

2019 2025< Lists of ADCs drugs have been approved by the FDA >

https://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin

https://en.wikipedia.org/wiki/Brentuximab_vedotin

https://en.wikipedia.org/wiki/Trastuzumab_emtansine

https://en.wikipedia.org/wiki/Inotuzumab_ozogamicin

https://en.wikipedia.org/wiki/Polatuzumab_vedotin

https://en.wikipedia.org/wiki/Enfortumab_vedotin

https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan

https://en.wikipedia.org/wiki/Sacituzumab_govitecan



• The global Immunotoxin Drug Market was valued at $1.62 billion in 2020 and is forecasted togrow at 9.6% CAGR between 2020 and 2026, culminating in 2026 global sales of $2.78 billion.

• To date, a total of 3 RITs have been approved by the FDA, including Denileukin diftitox (Ontak),tagraxofusp-erzs (ElzonrisTM), Moxetumomab pasudotox (LumoxitiTM)

• More than 60 immunotoxins are currently undergoing pre-clinical and clinical testing (Amani etal., 2020).

12

Immunotoxin : An emerging approach for a wide variety of cancer treatment

Name Company Format FDA approval Indication

OntakDenileukin diftitox

Eisai Corporation DAB389-IL2 1999 Cutaneous T-cell lymphoma

ElzonrisTagraxofusp-erzs

Stemline Therapeutics DAB-IL3 2018Blastic plasmacytoid dendritic cell neoplasm

LumoxitiMoxetumomab

AstraZeneca Anti-CD22 sdFv-PE38 2018 Hairy cell leukemia

ViciniumOportuzumab Monatox

Sesen BioAnti-EpCAM scFv-PE38

(Humanized Ab)

2020FDA Acceptance and P

riority Review

Non-muscle-invasive bladder cancer

$1.622m$2.116m

$2.795 m

2020 2023 2026

< Lists of Immunotoxin drugs have been approved by the FDA >

https://www.sciencedirect.com/science/article/pii/S0734975020301853#bb0020



• RIT has relative merits over Antibody Drug Conjugates, huge potential for the treatment of various cancer types

13

Comparison: ADC (Antibody Drug Conjugate) vs RIT (Recombinant Immunotoxin)

ADC: RIT:

ADC RIT Advantage

Key technology Conjugation, payload Translocation domain, Toxin Expandable toward drug delivery

Payload Chemical Bacterial, plant, marine proteinDrug manufacturing with recombinant DNA technology

Mechanism of action (MoA)Most commonly antitubulin agents,

lysosome requiredProtein synthesis inhibition,

No lysosome requiredTargeting intracellular receptors, cytosolic proteins, and cell organelles

Toxicitymost commonly peripheral neuropathy,

myelosuppressionVascular leak syndrome Ways to reduce toxicity are possible

Bystander effect Yes None No off-target toxicity

Target cell killing Mostly dividing cells Dividing and non-dividing cells Massive killing effect

MoA against standard chemotherapy

Overlapping Non-overlappingCombination therapy with chemotherapy is possible

No. of FDA approved drugs 10 3





OPTIMIZE IMMUNOTOXIN RESEARCH & DEVELOPMENT

Fatiabgen’s Core Assets

14



Fatiabgen has secured 6 issued patents, seeds for immunotoxin development

15

IP Portfolio

No Classification Title of Invention Registration No./Date

1

Protein Expression & Purification

Expression and purification method of biological active human FGF2 with human PDIb´a´ domain in Escherichia coli 10-1434734 (2014.08.20)

2 Soluble expression and purification method of active recombinant human Dkk2 10-1508052 (2015.03.26)

3 Soluble expression and purification method of active recombinant human CCL2 10-1508056 (2015.03.26)

4Growth FactorExpression & Purification

Expression Vector for Human Erythropoietin and Process for Production of Erythropoietin Using Thereof 10-1364864 (2014.12.12)

5 Expression and purification method of biologically active human LIF with human PDIb´a´ tag in Escherichia coli 10-1434739 (2014.08.20)

6

Protein Expression & Purification

Soluble overexpression and purification method of biological active recombinant human EC-SOD in Escherichia coli 10-1429342 (2014.08.05)



• Fatiabgen has various monoclonal antibodies specifically recognizing their targets.

16

Fatiabgen Assets: Monoclonal antibody library

Antibody collectionTarget

Antigen Antibody Antigen Antibody

CEA

2xNb4

Mesothelin

Nb02

Nb2 Nb11

Nb4.1 Nb18

Nb4 Nb24

Nb9 scFv

scFv

Mucin1

Nb1

HER2Nb17 Nb2

scFv Nb3

HGFRNb1

PSMA

Nb

scFv Nb2

EpCAMNb20 Nb3

scFv scFv

Frizzled7

NbGlypican3

Nb9

Nb2 scFv

Nb3

• Highly expression in cancer cells vs normal cells

• Clinicopathological relevance

• No or limited shedding

• Internalization capability

[Target selection criteria]

Target Indication

CEA Cholangiocarcinoma, colon, gastric cancer

HER2 Breast, pancreatic cancer

HGFR Cholangiocarcinoma, lung, gastric cancer

EpCAMCholangiocarcinoma, lung, breast, prostate, pancreatic, gastric cancer

Frizzled7 Hepatocellular carcinoma, gastric, breast, colon cancer

Mesothelin Mesothelioma, pancreatic cancer, ovarian cancer

Mucin1 Lung, pancreatic cancer

PSMA Prostate, pancreatic cancer

Glypican3 CholangiocarcinomaNb: Single domain antibody, scFv: Single chain variable fragment

[Consideration] Size, valencies, flexibility, epitope, PK



• Fatiabgen has investigated cell killing effects of various immunotoxins on cancer cells

17

Fatiabgen Assets: Immunotoxin library

Target-concentration dependent cell killing effectToxin

Classification toxin

Bacterial toxin Pseudomonas toxin, diphtheria toxin, shiga toxin

Mycotoxin Fungal toxins

Marine toxin Algae toxins

Phytotoxin Plant toxins including ricin

Venomes from land

animalsVenomes containing crotamine

• Cytotoxic substances naturally produced by living organisms(bacteria, fungus, plant, and animal)

• Appear in sizes ranging from small molecules to large proteins, and have diverse mechanisms of action

• Only small quantities of toxins damage cells

[Description][PE24]

[Crotamine]

• Cytolethal molecule to genetically attached to a targeting moiety • Strong cytotoxicity with low toxicity• Low immunogenicity

[Therapeutic application]

[Classification]



• Fatiabgen has secured protein expression system for process development advantage and high bioavailability

Fatiabgen Assets: Increased Solubility

18

High solubility and purity Solubilization test

[Protein expression with chaperone proteins]

M: MarkerC: CrudeI: Induction

P: PrecipitateS: Soluble

Induction at 37oC

[Protein expression with different competent cells]

Induction at 18oC

Induction at 37oC Induction at 18oC

Cultivation in E.coli BL21 (DE3)MBP-anti CEA (scFv)-PE24

1st ColumnMBP-affinity chromatography

Cleavage by TEV protease

2nd ColumnHis-affinity chromatography

Quantification

M

M: MarkerTEV: TEV cleavageAF: Affinity chromatography

[Protein purification]kDa

[Process]

Cloning Transformation in E.coli

Sequencing Induction

Competent cell selection

Chaperone selection

Protein purification

Cell disruptionChromatography

Solubility check

Cell lysates

18





Fatiabgen’s Pipeline Roadmap & Expenditure plan

19



• Fatiabgen’s growth strategy is to build the pipelines as well as develop platform technology

• Fatiabgen’s 3-year plan is to bring out key candidates for pre-clinical phase

• Collaborate with Y-Biologics to create novel candidates for Mesothelioma and Pancreatic cancer

20

Fatiabgen Pipeline Roadmap

Pipeline Indication Collaboration

Discovery

Preclinical Phase I Phase II Phase IIILead Selection Lead to Candidate

mAb screeningmAb

characterizationIn vitro/In vivo

PoCAb format

optimizationDrug deliveryoptimization

Toxin modification

FabG1-2139

Mesothelioma orPancreatic cancer

Y-Biologics

FabG1-3919

Small cell lung cancer In-House

FabT1-4290

Solid tumors in TME In-House

FabN1 Undisclosed In-House

Series B

2021 2022 ~ 20232024

~ 2025

Series A Series C

Beyond 2025



Expenditure Plan (2021 ~ 2025)

Fiscal Year Investment Plan Stage InvestorSeed

AmountPre-Valuation

3Q 2021 Establish additional R&D center in Daejeon

Stage A

Investment Bank /

Venture Capital

$5M $50M

2Q~4Q 2021 Talent Acquisition - Scientists & Researchers

2021-3Q~

2023

Research & Development• Pipeline Generation- mAb screening- PoC of recombinant immunotoxin in vitro, in vivo study• Platform Development- Drug delivery optimization- Toxin modification

Global Pharma

2024 ~ 2025

Preclinical study- Cell line development- Upstream/downstream process development- Chemistry, manufacturing and control (CMC) - GLP-tox- Formulation- GMP DS and DP production- IND filing

Stage B

IB/VC

$30M $150MPharma

Others

2026 Clinical study Series C N/A TBD TBD



Expenditure Plan (2021 ~ 2023)

Category Item No. Investment ($) Purpose Year

Set-up/Recruiting2nd Laboratory Set-up $100K R&D Center Set-up 2021

Talent Acquisition 10 ~ 15 $1.5Mn Labor Costs 2021 ~ 2022

R&D Platform/Pipeline Generation $2.5Mn Research & Development 2021 ~ 2023

Lab Equipment

IncuCyte 1 $250K Cell-based Assay 2021

Flow Cytometer 1 $150K Target expression, Antibody specificity 2021

Confocal microscopy 1 $500K Mode-of-Action study 2022

[IncuCyte] [Flow Cytometer] [Confocal Microscopy]



Fatiabgen R&D collaboration with world class partners

Antibody

• Research collaboration

- Screening the best mAb

- Act on the right target in the right place

• Drug engineering

- High stability in blood

- Drug delivery into the cytosol

Linker

• Building toxin library- Dr. Chun-Gu Park

• Organelle targeting- Dr. Jae-Ho Seo

Cytolytic toxin

• Providing Proof-of-Concept of drugs for clinical trial

• Exploiting competitive advantages of our drugs over competitor’s

• Getting rid of risk factors and increasing the success rate in development

• Providing the information on the scientific clues for clinical trial design

Research strategy

• Out-Licensing

• In-house development

Innovative drug development





Investment Trend – Antibody Drug Conjugates

24



• Most active investors by Stage in Antibody Drug Conjugates Market

• ADC M&A deals totaled $11.7B (16% of total disclosed biotech M&A)

• 19 IPOs up an average of 67% compared with the year 2019

25

Active Investors - ADC

Copyright 2019, Tracxn Technologies. All rights reserved



• Comparison of Total Funding raised by top companies in ADC Market

26

Comparison: Total Funding and Founded Year

Copyright 2019, Tracxn Technologies. All rights reserved



• Immunotoxin market leader, Molecular Templates (MTEM), is a clinical-stage biotech company that engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers.

27

Competitor Comparison

Category Molecular Templates (MTEM) Fatiabgen

Types of oncology Immunotoxin Immunotoxin

Establishment / Market Capital

2001 / $700Mn (Nasdaq) 2020 / $8.2Mn (pre-seeding)

Key investor Excel Venture, Aju IB, Sante Ventures, Longitude capital Seed stage

Revenue $18.85Mn None

Pipelines / Target

• MT-3724 / DLBCL (CD20)• MT-5111 / Multiple solid tumors (HER2)• TAK-169 / Multiple Myeloma (CD38)• MT-6402 / Solid tumors (PD-L1)

• FabG1-2139 / Mesothelioma & Pancreatic cancers • FabG1-3919 / SCLC• FabT1-4290 / TME• FabN1 / Nondisclosure

Key Technologies• Engineered version of Shiga-like Toxin A subunit• Ribosome inactivation + forced internalization + de-

immunization

• Conditional human antibody + deimmunized PE24• Novel mechanism of action to destroy cancer cells

using drug delivery• Proprietary toxin library

Location Austin, Texas Seoul, Korea

28

Documents

Innovating Novel Immunotoxin Antibody Assets